Verici Dx, a US-based developer of clinical diagnostics for organ transplant, has signed an exclusive global licensing agreement with Thermo Fisher Scientific. This agreement allows Thermo Fisher to further develop an assay for pre-transplant prognostic testing for the risk of early kidney rejection. Thermo Fisher will have the rights to develop and offer the assay as a Laboratory Developed Test (LDT) in the US and worldwide. The goal is to create a test that can stratify patients based on their immune response to a transplanted kidney, providing clinicians with valuable information for post-transplant and immunosuppressive management decisions. Sara Barrington, CEO of Verici Dx, expressed excitement about the collaboration with Thermo Fisher, stating it would accelerate the development of their technology. Nicole Brockway, President of Transplant Diagnostics at Thermo Fisher Scientific, highlighted the need for effective tests to identify the risk of transplant rejection early, hoping that this licensing agreement would lead to the development of a new prognostic assay and strengthen their portfolio of transplant testing solutions.
